Women’s Health

80 million unintended pregnancies occur each year worldwide. 38% of all pregnancies are unintended, 50% in the US.1

Unintended Pregnancies cost $11 billion each year in the US.2

Long acting reversible contraception is widely seen as the key to reducing the rate of unintended pregnancy.

Contraceptive CHOICE Project: 10,000 women were educated and surveyed on all available contraceptive options in the US and asked which method they would prefer to use if they did not have to pay anything for their contraception for three years. 56% of these women chose an IUD.3 56%. Despite this, only 5.5% of women practicing contraception (3.4% of all women of reproductive age) in the US currently use an IUD.4,5 There is a clear need for intervention from a company such as Bioceptive to help bridge that gap.

Only 40% of healthcare providers currently providing contraceptive services in California felt “very comfortable” inserting a Mirena IUS and only 60% with a Paragard IUD.6

The expulsion of IUDs occurs in 2 to 10% of IUD users within the first year of placement and the expulsion rate has been shown to be dependent upon the experience of the provider in placing the IUD at the desired position in the uterus.7,8,9

 

———————————————————————————————————————————————–

1. Speidel, Joseph, Cynthia C. Harper, and Wayne C. Shields. “The Potential of Long-acting Reversible Contraception to Decrease Unintended Pregnancy.” Contraception 78 (2008): 197-200.
2. Sonfield, Adam, Kathryn Kost, Rachel B. Gold, and Lawrence B. Finer. “The Public Costs of Births Resulting from Unintended Pregnancies: National and State-Level Estimates.” Perspective on Sexual and Reproductive Health 43.2 (2011): 94-102.
3. Secura, PhD, MPH, Gina M., Jenifer E. Allsworth, PhD, Tessa Madden, MD, MPH, Jennifer L. Mullersman, BSN, and Jeffrey F. Peipert, MD, PhD. “The Contraceptive CHOICE Project: Reducing Barriers to Long-acting Reversible Contraception.” American Journal of Obstetrics & Gynecology 203.115 (2010): e1-7.
4. “World Contraceptive Use 2007.” Department of Economic and Social Affairs, Population Division. United Nations, Jan. 2008.
5. Mosher WD, Jones J. Use of contraception in the United States: 1982–2008. Centers for Disease Control and Prevention: National Center for Health Statistics. Vital Health Stat 23(29). 2010.
6. Harper, PhD, Cynthia C., Maya Blum, MPH, Heike Thiel De Bocanegra, PhD, MPH, Philip D. Darney, MD, MSc, Joseph J. Speidel, MD, MPH, Michael Policar, MD, and Eleanor A. Drey, MD, EdM. “Challenges in Translating Evidence to Practice: The Provision of Intrauterine Contraception.” Obstetrics and Gynecology 111.6 (2008): 1359-369.
7. Harrison-Woolrych, M., J. Ashton, and D. Coulter. “Insertion of the Multiload Cu375 Intrauterine Device; Experience in over 16,000 New Zealand Women.” Contraception 66.6 (2002): 387-91.
8. Bayer HealthCare Pharmaceuticals. Mirena: Prescribing Information. Wayne, NJ: Bayer HealthCare Pharmaceuticals, 2009

9. Duramed Pharmaceuticals. Prescribing Information: ParaGard T380A, Intrauterine Copper Contraceptive. Pomona, NY: Duramed Pharmaceuticals, 2006.

Comments are closed.